Bayer Aleve Cold & Sinus
This article was originally published in The Tan Sheet
Executive Summary
FDA grants the line extension three years of Hatch/Waxman marketing exclusivity, expiring Nov. 29, 2002. The 220 mg naproxen sodium/120 mg pseudoephedrine hydrochloride combo approved by FDA Nov. 29 has not yet launched (1"The Tan Sheet" Dec. 6, 1999, p. 3)